ArticleMolecules (Basel, Switzerland)2026
MBind: A Web-Based Platform for Metalloprotein and Nonmetalloprotein Docking with Optional ML Docking Integration.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metalloprotein docking is difficult because it requires precise preparation of the grid box, charge assignment, and metal coordination geometry. Many current graphical user interfaces (GUIs) do not support these steps well. Here, we present MBind v2026, a web-based GUI that combines AutoDock Vina, AutoGrid4 and AutoDock4 into a single workflow for standard docking and metalloprotein docking. The interface also has the optional machine learning (ML) docking program GNINA v1.0. The main validated metalloprotein workflow in MBind is based on AutoDock4Zn parameterization for zinc, while preliminary workflows for magnesium, iron, and copper are also included. MBind was benchmarked on eight zinc metalloproteins and eight nonmetalloprotein targets. Its performance was compared with ML pose prediction methods (GNINA v1.0, EquiBind v2026, TankBind v2026, and GAABind v2026), cofolding models (Boltz-2 v2026, and AlphaFold 3 v2026), ML affinity prediction tools (StructureNet v2026, GNNSeq v2026, and PLAIG v2026), and non-ML docking tools (SwissDock v2026, CB-Dock2 v2026, Webina v2026, 1-ClickDock v2026, and MolModa v1.01). Pose accuracy was measured by symmetry-aware ligand RMSD using DockRMSD v1.1 under redocking conditions with co-crystal-defined binding sites. Binding energy trends were evaluated by comparing docking scores with IC50-derived ΔG values using mean absolute error. On the zinc metalloprotein benchmark set, MBind produced a mean RMSD of 0.49 Å. On the nonmetalloprotein set, the mean RMSD was 0.62 Å. These results show that MBind can execute zinc metalloprotein and nonmetalloprotein docking workflows through a web-based interface, while the preliminary Mg, Fe, and Cu workflows require additional validation. The MBind GUI web-based platform is publicly available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.